Next Article in Journal
(E)-1-(2-Aminophenyl)-3-(4-chlorophenyl)prop-2-en-1-one
Previous Article in Journal
A Convenient Four-Step Synthesis of 1-{β-[3-(4-Methoxy-phenyl)Propoxy]-4-Methoxyphenethyl}-1H-Imidazole Hydrochloride as a Probing Tool for SOCE Assays
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

5-[(3-Fluorophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)methyl]-6-hydroxy-1,3-dimethylpyrimidine-2,4(1H,3H)-dione

1
Department of Chemistry, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia
2
Department of Chemistry, Faculty of Science, Alexandria University, P. O. Box 426, Ibrahimia, Alexandria 21321, Egypt
3
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P. O. Box 2457, Riyadh 11451, Saudi Arabia
4
Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura 35516, Egypt
*
Author to whom correspondence should be addressed.
Molbank 2016, 2016(4), M910; https://doi.org/10.3390/M910
Submission received: 20 July 2016 / Revised: 20 August 2016 / Accepted: 28 September 2016 / Published: 30 September 2016

Abstract

:
5-[(3-Fluorophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)-methyl]-6-hydroxy-1,3-di-methylpyrimidine-2,4(1H,3H)-dione 3 was synthesized via a multicomponent reaction. The Aldol–Michael addition reactions of N,N-dimethylbarbituric acid, cyclohexane-1,3-dione, and 3-fluorobenzaldehyde in aqueous solution gave the product in high yield. The molecular structure of the compound was confirmed by spectroscopic methods and X-ray crystallography. The title compound (C19H19FN2O5·H2O) crystallizes in the Monoclinic form, P21/c, a = 7.8630 (5) Å, b = 20.0308 (13) Å, c = 11.3987 (8) Å, β = 104.274 (3)°, V = 1739.9 (2)° Å3, Z = 4, Rint = 0.117, wR(F2) = 0.124, T = 100 K.

Graphical Abstract

1. Introduction

The barbituric acid skeleton represents an important structural motif that is embodied in a number of pharmaceutical agents with activities including anti-osteoporosis [1,2,3], anticonvulsant [4,5], urease inhibition [6,7], sedation, anesthesia [8,9], hypnosis [10], anti-oxidant [11], radio-sensitization, tyrosinase or alpha-glucosidase inhibition [12,13], anti-bacterial [14], anti-fungal [14], anti-cancer [14], and anxiolytic effects [3]. Many of these representatives are in clinical use as hypnotic and anti-inflammatory drugs; for example, sodium pentothal, phenobarbital, veronal, seconal, and bucolome [8,9]. We have synthesized a new pyrimidine derivative through a tandem Aldol–Michael reaction in aqueous medium. The desired compound was characterized by spectroscopic techniques and by X-ray single crystal analysis.

2. Results

The title compound 5-[(3-fluorophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)-methyl]-6-hydroxy-1,3-dimethylpyrimidine-2,4(1H,3H)-dione was synthesized following a reported procedure by Barakat et al. [15] (Scheme 1). The chemical reagents and solvents used in this study are commercially available. This reaction proceeds efficiently at room temperature (RT) in water and it is mediated by NHEt2. The structure of the synthesized compound was characterized using spectroscopic techniques like IR, 1H-, and 13C-NMR, GCMS, and elemental analysis. A suitable single crystal was grown in a mixture of dichloromethane/ethanol/diethyl ether and was used for X-ray diffraction analysis.

3. Discussion

Single-Crystal X-Ray Diffraction Study

The structure of 5-[(3-fluorophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)-methyl]-6-hydroxy-1,3-dimethyl-pyrimidine-2,4(1H,3H)-dione was confirmed by X-ray crystal structure analysis. The features of the structure refinements, crystallographic data, and conditions retained for the intensity data collection are given in Table 1. The bond angles and interatomic distances are listed in Table 2 [16,17]. COD ID 3000079 contains the supplementary crystallographic data for this paper.
In the unit cell (Figure 1), the title compound was crystallized with one molecule of water as a solvent, which forms strong hydrogen bonds with O1, O2, and O4. The F atom shows disorder over two positions, with site occupancies of 0.773 (4) and 0.227 (4). The 6-hydroxy-1,3-dimethylpyrimidine-2,4(1H,3H)-dione ring (C1/N1/C3/N2/C5/C6) was found to adopt nearly dihedral angles with the 2,6-dihydroxycyclohex-1-en ring (C8–C13) and 3-fluorophenyl ring (C14–C19) as 64.56 (5) and 68.38 (3)°, respectively. On the other hand, the 2,6-dihydroxycyclohex-1-en ring forms a dihedral angle of 46.90 (5)° with the 3-fluorophenyl ring. The title compound having bond lengths of C5=C6 and C8=C9 are 1.369 (4) and 1.373 (4) Å, respectively, and these are typical carbon carbon double bonds. In the crystal structure, molecules are linked via a network of intermolecular hydrogen bonds (Table 3, Figure 2).

4. Materials and Methods

4.1. General

The chemicals were purchased from Aldrich (Riedstraße, Germany) and Fluka (Buchs, Switzerland), and were used without further purification, unless otherwise stated. The IR spectrum was measured for a KBr pellet on a Nicolet 6700 FT-IR spectrophotometer (Thermo Fisher Scientific, Madison, WI, USA).The NMR spectra were recorded on a Jeol-400 NMR spectrometer (Tokyo, Japan). 1H-NMR (400 MHz) and 13C-NMR (100 MHz) were recorded in deuterated dimethylsulfoxide (DMSO-d6). Chemical shifts (δ) are reported in ppm and J -coupling constants are given in Hz. Mass spectrometric analysis was conducted by using ESI mode on an AGILENT Technologies 6410–triple quad LC/MS instrument (Santa Clara, CA, USA). Elemental analysis was carried out on a Perkin Elmer 2400 Elemental Analyzer, CHN mode (Waltham, MA, USA). X-ray crystal structure analysis was performed on a Bruker APEX-II D8 Venture area diffractometer (Bruker AXS GmbH, Karlsruhe, Germany).

4.2. Synthesis of 5-[(3-Fluorophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)-methyl]-6-hydroxy-1,3-di-methyl-pyrimidine-2,4(1H,3H)-dione

A mixture of 1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (1.0 mmol), cyclohexane-1,3-dione (1.0 mmol), and 3-fluorobenzaldehyde (1.0 mmol) in 2.0 mL of H2O was charged into a 10 mL round bottom flask mediated by diethylamine (1.0 mmol). The reaction mixture was stirred at room temperature for 24 h, until TLC (Merck Silica Gel 60 F–254; eluent: 30% EtOAc/n-hexane) showed that the reactants were completely consumed. After completion of the reaction, the solid product was collected by filtration and dried. The compound was obtained as white crystals by crystallization using a mixture of (CH2Cl2/EtOH/Et2O).
White crystalline compound; Yield 92%, m.p.: 113–115 °C; 1H-NMR (400 MHz, DMSO-d6) δ: 7.21 (t, J = 7.3 Hz, 1H, Ph), 6.91 (s, 1H, Ph), 6.83 (d, J = 7.3 Hz, 2H, Ph), 5.90 (s, 1H, benzyl-H), 3.16 (m, 2H, CH2), 2.97 (s, 6H, CH3), 2.20 (t, J = 7.3 Hz, 2H, CH2), 1.75 (t, J = 7.3 Hz, 2H, CH2); 13C-NMR (100 MHz, DMSO-d6) δ: 191.7, 168.1, 167.7, 152.2, 143.8, 129.2, 124.6, 114.9, 112.5, 112.0, 51.9, 42.1, 31.8, 28.0, 20.2; IR (KBr, cm−1) νmax = 3155, 2928, 1660, 1550, 1256; Anal. calcd. for C19H19FN2O5: C, 60.96; H, 5.12; N, 7.48; Found: C, 60.97; H, 5.11; N, 7.50]; LC/MS (ESI, m/z): [M + 1], found 375.37, C19H19FN2O5: 374.37.

5. Conclusions

A new barbituric acid derivative was synthesized via a green protocol. The molecular structure of the synthesized compound was investigated by spectroscopic tools and X-ray single crystal diffraction technique.

Supplementary Materials

The following are available online at https://www.mdpi.com/1422-8599/2016/4/M916, NMR spectra of compounds 24.
Supplementary File 1Supplementary File 2Supplementary File 3

Acknowledgments

The project was supported by King Saud University, College of Science, Department of Chemistry.

Author Contributions

A.B. and A.M.A conceived and designed the experiments; S.A. performed the experiments; M.S.I. and M.A. analyzed the data; H.A.G. carried out the X-ray single crystal; A.B. contributed reagents/materials/analysis tools; A.B. wrote the paper.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bojarski, J.T.; Mokrocz, J.L.; Barton, H.J.; Paluchowska, M.H. Recent progress in barbituric acid chemistry. Adv. Heterocycl. Chem. 1985, 38, 229–297. [Google Scholar]
  2. Sans, S.R.G.; Chosaz, M.G. Historical aspects and applications of barbituric acid derivatives. Pharmazie 1988, 43, 827–829. [Google Scholar]
  3. Taylor, J.B. Modern Medical Chemistry; Prentice Hall: New York, NY, USA, 1994. [Google Scholar]
  4. Holtkamp, M.; Meierkord, H. Anticonvulsant, antiepileptogenic, and antiictogenic pharmacostrategies. Cell. Mol. Life Sci. 2007, 64, 2023–2041. [Google Scholar] [CrossRef] [PubMed]
  5. Archana, S.; Srivastava, V.K.; Kumar, A. Synthesis of newer indolyl/phenothiazinyl substituted 2-oxo/thiobarbituric acid derivatives as potent anticonvulsant agents. Arzneim. Forsch. Drug Res. 2002, 52, 787–791. [Google Scholar] [CrossRef]
  6. Barakat, A.; Al-Majid, A.M.; Lotfy, G.; Arshad, F.; Yousuf, S.; Choudhary, M.I.; Ashraf, S.; Ul-Haq, Z. Synthesis and dynamics studies of barbituric acid derivatives as urease inhibitors. Chem. Cent. J. 2015, 9, 63. [Google Scholar] [CrossRef] [PubMed]
  7. Ul-Haq, Z.; Ashraf, S.; Al-Majid, A.M.; Barakat, A. 3D-QSAR studies on barbituric acid derivatives as urease inhibitors and the effect of charges on the quality of a model. Int. J. Mol. Sci. 2016, 17, 657. [Google Scholar] [CrossRef] [PubMed]
  8. Goodman, L.S.; Limbird, E.L.; Milinoff, P.B.; Ruddon, R.W.; Gilman, A.G. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics, 9th ed.; McGraw-Hill: New York, NY, USA, 1996; p. 471. [Google Scholar]
  9. Wolff, M.E. Burger’s Medicinal Chemistry and Drug Discovery; Wiley: New York, NY, USA, 1997. [Google Scholar]
  10. Chandler, L.J.; Leslie, S.W.; Gonzales, R. 5-(2-Cyclohexylideneethyl)-5-ethyl barbituric acid (CHEB): Correlation of hypnotic and convulsant properties with alterations of synaptosomal 45Ca2+ influx. Eur. J. Pharm. 1986, 126, 117–123. [Google Scholar] [CrossRef]
  11. Barakat, A.; Al Majid, A.M.A.; Al-Najjar, H.J.; Mabkhot, Y.N.; Javaid, S.; Yousuf, S.; Choudhary, M.I. Zwitterionic pyrimidinium adducts as antioxidants with therapeutic potential for nitric oxide scavenger. Eur. J. Med. Chem. 2014, 84, 146–154. [Google Scholar] [CrossRef] [PubMed]
  12. Barakat, A.; Soliman, S.M.; Al-Majid, A.M.; Lotfy, G.; Ghabbour, H.A.; Fun, H-K.; Yousuf, S.; Choudhary, M.I.; Wadood, A. Synthesis and structure investigation of novel pyrimidine-2,4,6-trione derivatives of highly potential biological activity as anti-diabetic agent. J. Mol. Strut. 2015, 1098, 365–376. [Google Scholar] [CrossRef]
  13. Barakat, A.; Islam, M.S.; Al-Majid, A.M.; Ghabbour, H.A.; Fun, H-K.; Javed, K.; Imad, R.; Yousuf, S.; Choudhary, M.I.; Wadood, A. Synthesis, in vitro biological activities and in silico study on dihydropyrimidines derivatives. Bioorg. Med. Chem. 2015, 23, 6740–6748. [Google Scholar] [CrossRef] [PubMed]
  14. Sharma, S.K.; Kumar, P.; Narasimhan, B.; Ramasamy, K.; Mani, V.; Mishra, R.K.; Majeed, A.B.A. Synthesis, antimicrobial, anticancer evaluation and QSAR studies of 6-methyl-4-[1-(2-substituted-phenylamino-acetyl)-1H-indol-3-yl]-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl esters. Eur. J. Med. Chem. 2012, 48, 16–25. [Google Scholar] [CrossRef] [PubMed]
  15. Al-Majid, A.M.; Barakat, A.; Al-Najjar, H.J.; Mabkhot, Y.N.; Ghabbour, H.A.; Fun, H.-K. Tandem Aldol-Michael reactions in aqueous diethylamine medium: A greener and efficient approach to bis-pyrimidine derivatives. Int. J. Mol. Sci. 2013, 14, 23762–23773. [Google Scholar] [CrossRef] [PubMed]
  16. Sheldrick, G.M. A short history of SHELX. Acta Crystallogr. 2008, A64, 112–122. [Google Scholar] [CrossRef] [PubMed]
  17. Brucker. APEX2, SAINT and SADABS, Brucker AXS Inc.: Madison, WI, USA, 2009.
Scheme 1. Synthesis of the target compound.
Scheme 1. Synthesis of the target compound.
Molbank 2016 m910 sch001
Figure 1. The molecular structure of the target compound showing 40% probability displacement ellipsoids for non-H atoms.
Figure 1. The molecular structure of the target compound showing 40% probability displacement ellipsoids for non-H atoms.
Molbank 2016 m910 g001
Figure 2. H-bonding network in the crystal structure of the title compound viewed as 3D network; dotted lines indicate intermolecular interactions.
Figure 2. H-bonding network in the crystal structure of the title compound viewed as 3D network; dotted lines indicate intermolecular interactions.
Molbank 2016 m910 g002
Table 1. Crystal data, data collection, and refinement.
Table 1. Crystal data, data collection, and refinement.
Crystal Data
Chemical formulaC19H19FN2O5·H2O
Mr392.38
Crystal system, space groupMonoclinic, P21/c
Temperature (K)100 K
a, b, c (Å)7.8630 (5), 20.0308 (13), 11.3987 (8)
β (°)104.274 (3)
V3)1739.9 (2)
Z4
Radiation typeMo Kα
µ (mm−1)0.12
Crystal size (mm)0.34 × 0.22 × 0.09
Data Collection
DiffractometerD8 Venture area detector
Absorption correctionmulti-scan, SADABS V2014/3
No. of measured, independent, and observed [I > 2σ(I)] reflections18454, 3070, 1995
(sin θ/λ)max−1)0.594
Rint0.117
Refinement
R[F2 > 2σ(F2)], wR(F2), S0.055, 0.124, 1.05
No. of reflections3070
No. of parameters288
No. of restraints2
H-atom treatmentH atoms treated by a mixture of independent and constrained refinement
(Δ/σ)max1.208
Δρmax, Δρmin (e Å−3)0.28, −0.27
Table 2. Selected geometric parameters (Å, °).
Table 2. Selected geometric parameters (Å, °).
F1–C161.344 (4)N1–C11.411 (4)
F1X–C181.268 (16)N1–C21.465 (4)
O1–C11.243 (4)N1–C31.370 (4)
O2–C31.229 (4)N2–C41.470 (4)
O3–C51.306 (4)N2–C51.388 (4)
O4–C91.324 (4)N2–C31.374 (4)
O5–C131.257 (4)
C2–N1–C3116.9 (2)O3–C5–C6125.3 (3)
C1–N1–C3124.3 (3)O3–C5–N2113.0 (3)
C1–N1–C2118.7 (2)N2–C5–C6121.7 (3)
C3–N2–C4118.5 (2)O4–C9–C10116.9 (3)
C3–N2–C5121.9 (3)O4–C9–C8119.6 (3)
C4–N2–C5119.4 (2)O5–C13–C12116.2 (3)
O1–C1–N1117.7 (3)O5–C13–C8122.7 (3)
O1–C1–C6125.3 (3)F1–C16–C15117.8 (3)
N1–C1–C6117.0 (3)F1–C16–C17118.4 (3)
O2–C3–N2121.3 (3)F1X–C18–C17114.7 (9)
N1–C3–N2116.2 (3)F1X–C18–C19124.3 (9)
O2–C3–N1122.5 (3)
Table 3. Hydrogen-bond geometry (Å, °).
Table 3. Hydrogen-bond geometry (Å, °).
D–H···AD–HH···AD···AD–H···A
O1W–H2OW···O2 i1.09 (6)1.74 (6)2.815 (3)171 (5)
O3–H1O3···O51.02 (4)1.44 (4)2.454 (3)175 (4)
O4–H1O4···O1W ii1.01 (4)1.62 (4)2.622 (3)173 (4)
O1W–H1OW···O1 iii1.00 (3)1.92 (5)2.754 (3)138 (4)
O1W–H1OW···O4 iii1.00 (3)2.34 (4)3.051 (3)127 (4)
C2–H2A···F1 iv0.96002.40003.300 (4)156.00
C11–H11B···O3 v0.97002.54003.288 (4)133.00
Symmetry codes: (i) x, −y + 1/2, z + 3/2; (ii) x, −y + 1/2, z−1/2; (iii) −x, y−1/2, −z + 3/2; (iv) −x, y + 1/2, −z + 1/2; (v) x, −y + 1/2, z + 1/2.

Share and Cite

MDPI and ACS Style

Barakat, A.; Ghabbour, H.A.; Atef, S.; Al-Majid, A.M.; Shahidul Islam, M.; Ali, M. 5-[(3-Fluorophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)methyl]-6-hydroxy-1,3-dimethylpyrimidine-2,4(1H,3H)-dione. Molbank 2016, 2016, M910. https://doi.org/10.3390/M910

AMA Style

Barakat A, Ghabbour HA, Atef S, Al-Majid AM, Shahidul Islam M, Ali M. 5-[(3-Fluorophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)methyl]-6-hydroxy-1,3-dimethylpyrimidine-2,4(1H,3H)-dione. Molbank. 2016; 2016(4):M910. https://doi.org/10.3390/M910

Chicago/Turabian Style

Barakat, Assem, Hazem A. Ghabbour, Saleh Atef, Abdullah Mohammed Al-Majid, Mohammad Shahidul Islam, and M. Ali. 2016. "5-[(3-Fluorophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)methyl]-6-hydroxy-1,3-dimethylpyrimidine-2,4(1H,3H)-dione" Molbank 2016, no. 4: M910. https://doi.org/10.3390/M910

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop